CannAssist (OTCQB: CNSC), a biotechnological pharmaceutical and wellness company, believes that its proprietary CiBiDinol technology will be a game-changer. According to a recent article, “the company believes that the amount of CBD needed to achieve the targeted therapeutic effects can be reduced significantly, resulting in reduced costs for both manufacturers and consumers.” CBD-based products “reduce inflammation while providing pain relief.” They are also the preferred option because they are “a gentler way to relieve pain and reduce inflammation,” unlike mainstream pharmaceuticals that have dangerous toxicity levels. CiBiDinol’s high efficacy per dose was the subject of “testing conducted via third-party services that confirmed these claims, suggesting that products created with CiBiDinol demonstrate a 400% increase in skin penetration along with a 300% increase in the rate of gut absorption when compared to regular oil-based CBD.” The article details how CNSC created CiBiDinol and the reason for the efficacy.
To view the full article, visit https://ibn.fm/7Kdgi
About CannAssist International Corporation
CannAssist, the parent company of Xceptor Labs, produces and sells its CiBiDinol technology, formulated using a proprietary process developed by the company’s founder, Mark Palumbo. Research and development aimed at enhancing the bioavailability of oil-soluble molecules resulted in the company’s CiBiDinol technology. CiBiDinol is the driving force behind CannAssist’s Xceptol brand of consumable and topical products. Possessing a National Drug Code (“NDC”), the highest quality ingredients and the game-changing CiBiDinol, Xceptol Pain Cream is a CBD product with industry-defining reliability and compliance. CannAssist believes Xceptol represents the next step for CBD products. CBD is a non-psychoactive compound found in hemp. View the company’s products on RangeMe, an online platform that enables retail buyers to efficiently discover consumer-ready, innovative and emerging products while empowering suppliers to manage and grow their brands with the tools, insights and services they need. For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.